ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1362	National Cancer Institute	Html	en	Hot Flashes and Night Sweats (PDQ®)–Health Professional Version	Expert-reviewed information summary about causes and treatment of hot flashes and night sweats in cancer patients.	hot flash scores 0.45918 tamoxifen-induced hot flashes 0.487401 Loprinzi CL 0.545839 menopausal symptoms 0.464059 Barton DL 0.475444 nocturnal hot flashes 0.494473 black cohosh 0.488248 androgen deprivation therapy 0.448869 clinical trial 0.448391 breast cancer treatment 0.460098 breast cancer patients 0.474226 postmenopausal breast cancer 0.456276 hot flashes merits 0.487946 Natl Cancer Inst 0.459556 breast cancer survivors 0.509665 North Central Cancer 0.472407 hot flash reduction 0.458714 hot flashes 0.905213 hormone replacement therapy 0.476539 et al. 0.506432 women 0.50642 core body temperature 0.45737 night sweats 0.457026 study 0.456946 stage breast cancer 0.454333	hot flash studies 0.449594 hot flushes 0.465978 breast cancer diagnosis 0.451556 postmenopausal hot flashes 0.500892 breast cancer recurrence 0.47207 hot flash management. 0.448239 PUBMED Abstract 0.549613 Cancer Res Treat 0.462211 nighttime hot flashes 0.501942 hot flash frequency 0.50736 menopausal hot flashes 0.487616 Cancer Treatment Group 0.476248 hot flash management 0.49365 postmenopausal women 0.477394 breast cancer risk 0.486953 Clin Oncol 0.505954 receptor–positive breast cancer 0.451466 breast cancer 0.743246 randomized controlled trial 0.545918 hot flash 0.591793 healthy postmenopausal women 0.454945 prostate cancer 0.455636 placebo-controlled trial 0.450402 Central Cancer Treatment 0.476295	CLICK HERE
1394	National Cancer Institute	Html	en	Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors).	patient selection factors 0.438228 tumor cell types 0.413939 functional tumors 0.556939 slow-growing tumors 0.428195 pituitary tumors 0.418826 functional pancreatic neuroendocrine 0.426256 islet cell tumors 0.811481 preoperative dual-phase thin-section 0.348132 bone metastases 0.398217 islet cell cancers 0.399777 distinctive metabolic effects 0.341484 secondary endocrine tumors 0.452606 liver metastases 0.990586 unresectable liver metastases 0.497768 endocrine pancreas glands 0.386 metastatic disease 0.427564 sporadic islet cell 0.397131 resectable liver metastases 0.506505 venous sampling 0.390094 surgical resection series 0.389796 visible liver metastases 0.615044 liver neuroendocrine metastases 0.512043 individual tumors 0.388972 progressive pancreatic NETs 0.411807 clinical manifestations 0.349816	percutaneous alcohol ablation 0.339566 antihormonal pharmacologic therapy 0.339279 conventional imaging techniques 0.33881 radiofrequency ablation 0.342021 pancreatic resection 0.466639 pancreatic islets 0.36916 ulcer-producing Zollinger-Ellison syndrome 0.354188 somatostatin-receptor scintigraphy 0.356211 slow-growing metastatic islet 0.423125 pancreatic NETs 0.575547 technically demanding tests 0.350314 multiple endocrine neoplasia 0.362304 retrospective case series 0.340498 hormonally functional tumors 0.47568 tumor suppressor gene 0.392672 pancreatic islet cell 0.465855 overall tumor burden 0.363718 grossly visible liver 0.505977 MEN-1 syndrome 0.346786 pancreatic neuroendocrine tumors 0.701933 liver resection 0.37949 arterial stimulation 0.345171 common exocrine adenocarcinomas 0.348715 preoperative localization studies 0.4603	CLICK HERE
1452	National Cancer Institute	Html	en	Cigarette Smoking: Health Risks and How to Quit (PDQ®)–Health Professional Version	Expert-reviewed information summary about research and guidelines focused on the prevention and cessation of cigarette smoking.	smoking cessation strategy 0.633721 smoking cessation rates 0.605741 quit attempt 0.552085 effective smoking cessation 0.580922 gradual cessation group 0.483049 abrupt cessation 0.562882 prolonged validated smoking 0.480554 lung cancer 0.658405 tobacco cessation 0.463262 smoking cessation pharmacotherapies 0.597527 abrupt smoking cessation 0.601297 pipe tobacco smoking 0.505275 current smoking 0.475722 gradual cessation arm 0.465437 nicotine replacement therapy 0.54532 randomized trial 0.492165 Smoking cessation counseling 0.609156 receptor partial agonist 0.460896 area-level smoking prevalence 0.513667 smoking reduction 0.49426 smoking behavior 0.469981 smoking cessation treatment 0.588411 smoking prevalence data 0.513642 tobacco products 0.485537	abrupt cessation arm 0.472163 smoking cessation 0.926558 vs abrupt cessation 0.475821 adult cigarette smoking 0.474818 gradual cessation method 0.466403 cigarette smoking cessation 0.573293 cigarette smoking 0.62168 smoking cessation pharmacotherapy 0.595082 varenicline 0.542592 tobacco smoking 0.505702 smoking cessation rate. 0.602815 gradual cessation 0.501212 abrupt cessation group 0.489713 nicotinic acetylcholine receptor 0.464069 self-reported smoking abstinence 0.502629 smoking abstinence 0.574891 cigarette smoking prevalence 0.566333 randomized controlled trial 0.482431 6-month cessation rates 0.474432 nicotine patch 0.531368 smoking cessation intervention 0.590903 usual smoking patterns 0.480697 lung cancer mortality 0.510576 varenicline group 0.534998	CLICK HERE
1610	National Cancer Institute	Html	en	Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version	Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are composed of three major myeloid disorders: chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myeloid leukemia (aCML). Learn about the clinical features and treatment of these leukemias.	JMML 0.47142 5-year estimated probability 0.444988 evidence 0.458611 host disease grade 0.440441 anemia supervenes 0.445725 various chemotherapy regimens 0.572089 platelet-derived growth factor 0.511436 Leukemia Group 0.448642 white blood cells 0.44993 Myelodysplastic/ Myeloproliferative Neoplasms 0.440718 CMML 0.717566 marrow stem cell 0.463204 myelomonocytic leukemia 0.462437 HLA-matched unrelated individuals 0.444789 toxic effects 0.442066 bone marrow aplasia 0.560704 chronic myelomonocytic leukemia 0.449424 transplant-related mortality 0.457149 World Health Organization 0.564993 erythropoietic growth factors 0.554859 median age 0.543021 level 0.460994 randomized trial 0.458448 patients 0.901262 monthly maintenance 0.44579	randomized clinical trial 0.484352 major defining feature 0.454521 complete remission 0.448646 proliferative features 0.448887 DNA methyltransferase 0.449167 et al. 0.534469 young MDS patients 0.511634 follow-up study 0.441281 Complete hematologic remissions 0.570636 JMML leukemia cells 0.462656 pyrimidine-analog antimetabolite 0.44631 stem cell 0.531211 single-agent therapy 0.444312 13-cis retinoic acid 0.524469 transfusion requirements 0.448178 Median actuarial survival 0.504944 median duration 0.676959 nucleoside azacitidine 0.478539 particularly poor prognosis. 0.444869 patient survival data. 0.445943 bone marrow 0.729115 total-body radiation therapy 0.553338 allogeneic stem cell 0.441128 Juvenile myelomonocytic leukemia 0.458499	CLICK HERE
1927	National Cancer Institute	Html	es	Tratamiento del linfoma de Hodgkin infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin infantil.	siguientes procedimientos 0.539535 células madre 0.949818 estadio iv 0.500925 adultos jóvenes 0.452563 órgano cercano.ampliar linfoma 0.561365 siguientes elementos 0.448931 sudores nocturnos 0.484622 faja ajustadora 0.430459 siguientes especialistas 0.43177 siguientes tipos 0.443725 vía oral 0.419326 rayos x 0.473568 Hodgkin Lymphoma 0.582459 abdomen).ampliar linfoma 0.535694 detecte.ampliar exploración 0.434601 enlace drugs approved 0.498183 escáner tep 0.492453 niño ayuda 0.424524 estadio iiies 0.760474 riesgo intermedio 0.462626 efectos tardíos 0.664689 estadio ie 0.575058 células anormales.ampliar aspiración 0.485872	PDQ Efectos tardíos 0.461638 National Cancer Institute 0.420283 sustancia quizás 0.427861 siguientes lugares 0.433237 siguientes riesgos 0.418851 Instituto Nacional 0.434896 PDQ Tratamiento 0.682769 estadio iie 0.500587 Hodgkin recién 0.557678 explorador tep 0.443167 estadio e 0.45134 nuevos tipos 0.421275 Physician Data Query 0.471298 posibles efectos 0.420063 infancia quizás 0.428464 estadio iiis 0.959473 ósea fabrica glóbulos 0.493208 pelvis.ampliar imágenes 0.420331 distinta intensidad 0.419212 almacena células 0.485736 siguientes pruebas 0.485604 siguientes estadios 0.440037	CLICK HERE
1985	National Cancer Institute	Html	es	Descripción del tratamiento de tumores de encéfalo y de médula espinal infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de tumores de encéfalo infantiles.	espinal infantiles.ampliar punción 0.671368 Organización Mundial 0.330213 células madre 0.838888 efectos secundarios meses 0.514746 siguientes aspectos 0.364078 vía oral 0.337627 encéfalo benignos 0.752955 PDQ Descripción 0.372391 efectos tardíos 0.660507 PDQ correspondiente 0.464116 tumor subtipo 0.432726 PDQ Efectos tardíos 0.450037 cáncer.ampliar aspiración 0.351047 Astrocitoma pilomixoide 0.336263 líquido cefalorraquídeo 0.817195 National Cancer Institute 0.340319 siguientes riesgos 0.328861	Instituto Nacional 0.370517 PDQ Tratamiento 0.975349 riesgo promedio 0.357023 presente sección 0.332468 siguientes signos 0.392336 nuevos tipos 0.34964 siguientes factores 0.362333 sistema nervioso central 0.653419 Physician Data Query 0.447911 gliomas astroblastoma 0.333341 pdq correspondiente tipo 0.412457 alto astrocitoma 0.3322 panel derecho 0.358602 espinal infantiles recién 0.572263 siguientes pruebas 0.390652 siguientes sumarios 0.353304 siguientes trastornos 0.347907	CLICK HERE
2114	National Cancer Institute	Html	es	Exámenes de detección del cáncer de hígado (hepatocelular) (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de hígado (hepatocelular).	hepatitis c 0.799278 PDQ Exámenes 0.723065 estudio marcadores 0.652784 siguientes efectos 0.659695 Physician Data Query 0.826748 Estados Unidos 0.932003 rayos x 0.659043 prevención revisa 0.639071 sustancias dañinas 0.671115	cuerpo usa 0.666699 ondas sonoras 0.6623 siguientes exámenes 0.740755 información ayuda 0.645281 National Cancer Institute 0.657644 siguientes riesgos 0.650336 siguientes sumarios 0.743208 Instituto Nacional 0.706872 múltiples funciones 0.667669	CLICK HERE
3419	National Cancer Institute	Html	es	Accidentes en plantas nucleares de electricidad y el riesgo de cáncer	Hoja informativa acerca de los riesgos del cáncer asociados con accidentes en plantas nucleares de electricidad. Incluye información para pacientes con cáncer que viven en una zona que puede haber sido afectada por un accidente en una planta nuclear.	Atomic Radiation 0.316837 United Nations 0.364483 accident―An epidemiological perspective 0.318721 Zablotska L 0.256274 assembly with scientific 0.304698 Chernobyl-related thyroid 0.281728 Nations Scientific Committee 0.309452 Ulanovsky AV 0.266554 case-control study 0.27312 Brenner AV 0.261036 altas dosis 0.502454 Health effects 0.274048 Cardis E 0.255707 Hatch M 0.715405 Instituto Nacional 0.562168 consecuente exposición 0.36176 related disorders among 0.314284 Chernobyl nuclear power 0.336354 causa cáncer 0.40919 Life Span Study 0.319261 Mykola DT 0.263715 Environmental Health Perspectives 0.308221 PubMed Abstract 0.845077 Finch SC 0.258873 Clinical Oncology 0.262917	Bouville A 0.255535 Chernobyl disaster 0.278477 Annex D 0.255425 Epidemiologic Reviews 0.264619 Amenaza Radiológica 0.258735 Individual thyroid 0.27723 workers from ukraine 0.329042 inhalar partículas 0.413261 Drozdovitch VV 0.265349 Ukraine related 0.277279 Ukranian-American study 0.271859 Contributions from long-lived 0.322355 quimioterapia sistémica 0.267728 Ionizing Radiation 0.316029 incident thyroid cancers 0.332215 Health Physics 0.266767 Chornobyl accident 0.268808 Ciencias Demográficas 0.257571 Belarus—part II 0.255864 thyroid cancers 0.38621 manejo médico 0.356172 medio ambiente 0.973732 Minenko VF 0.264858 Segunda Guerra Mundial 0.28983	CLICK HERE
3523	National Cancer Institute	Html	es	Estudio NCI-MATCH (Análisis Molecular para Selección de Tratamientos)	Información sobre el estudio del NCI: Análisis Molecular para Selección de Tratamientos (NCI-MATCH), en el cual los investigadores examinarán tejidos de tumor de pacientes con tumores sólidos y linfomas avanzados que han dejado de responder al tratamiento.	Tumor Profiling 0.554625 estudio match 0.941659 Investigación Oncológica 0.6022 MD Anderson 0.61416 Memorial Sloan-Kettering Cancer 0.578519 Clinical Trials 0.539697 posibles participantes 0.607033 C2 MET 0.546519 Life Sciences 0.627896 laboratorios foundation medicine 0.56991 Foundation Medicine 0.623082 Memorial Sloan-Kettering identificarán 0.577406 estudio comet 0.807536 Grupo Cambio 0.537516 met amp crizotinib 0.576245	como los costos 0.539059 seguro médico 0.533808 Cancer Center 0.605302 MD Anderson Cancer 0.572606 tratamiento inscribirán 0.618222 sk crizotinib 0.541473 cabo estudios 0.534561 Caris Life Sciences 0.579205 Investigación Oncológica ECOG-ACRIN 0.571301 Memorial Sloan-Kettering 0.625566 egfr mut afatinib 0.573282 NRG Oncology Group 0.568484 Iniciativa de Medicina 0.538366 Life Sciences identificarán 0.57351	CLICK HERE
15802	National Cancer Institute	Html	null	About the Blue Ribbon Panel	Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science.			CLICK HERE